We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tenet Healthcare's (THC) Q1 Earnings Beat, Shares Up 3.9%
Read MoreHide Full Article
Shares of Tenet Healthcare Corporation (THC - Free Report) gained 3.9% since it reported better-than-expected first-quarter 2023 earnings on Apr 25. The strong results stemmed from a well-performing Ambulatory Care segment, expanding patient volumes within the Hospital Operations segment and a moderated pace of contract labor costs. A hiked adjusted earnings per share (EPS) guidance for 2023 might have also instilled investors’ confidence in the stock.
Tenet Healthcare reported first-quarter 2023 adjusted earnings of $1.42 per share, which outpaced the Zacks Consensus Estimate by 22.4% and exceeded management’s expectations. However, the bottom line plunged 25.3% year over year.
Net operating revenues of $5,021 million rose 5.8% year over year in the quarter under review and outperformed the management’s estimate. The top line beat the consensus mark by 4%.
Q1 Performance
Adjusted net income from continuing operations of Tenet Healthcare tumbled 26.7% year over year to $154 million and surpassed management’s expectations. Adjusted EBITDA of $832 million declined 6.3% year over year in the first quarter.
Operating expenses increased 7.8% year over year to $4,471 million mainly due to increased salaries, wages and benefits coupled with higher supplies and other operating expenses. Also, the metric came higher than our estimate of $4,323.9 million.
Tenet Healthcare Corporation Price, Consensus and EPS Surprise
Hospital Operations and Other – The segment reported net operating revenues of $3,899 million in the quarter under review, up 2.7% year over year. The reported figure outpaced the Zacks Consensus Estimate of $3,802 million and our estimate of $3,778.4 million. The unit benefited on the back of growing adjusted admissions.
On a same-hospital basis, net patient service revenues inched up 1.1% year over year to $3,547 million.
Adjusted EBITDA of $405 million dropped 21.2% year over year in the first quarter but beat the consensus mark of $362 million. The metric suffered a blow due to declining COVID-related volume and acuity.
Ambulatory Care - Net operating revenues advanced 22.6% year over year to $905 million, higher than the Zacks Consensus Estimate of $829 million and our estimate of $838.1 million. Solid same-facility net surgical case growth, buyouts, the inauguration of new facilities, service line growth and higher pricing yield contributed to the segment’s performance.
Adjusted EBITDA climbed 20.6% year over year to $340 million in the first quarter and beat the consensus mark of $285 million. The metric received an impetus from prudent cost-curbing initiatives.
Conifer – The segment’s net operating revenues of $324 million remained flat year over year in the quarter under review. However, the reported figure surpassed the Zacks Consensus Estimate as well as our estimate of $321 million.
Adjusted EBITDA slid 5.4% year over year to $87 million but beat the consensus mark of $76 million. Earlier disclosed contract changes with Tenet Healthcare’s hospitals hurt the metric.
Financial Position (as of Mar 31, 2023)
Tenet Healthcare exited the first quarter with cash and cash equivalents of $766 million, which decreased 10.7% from the 2022-end figure. Total assets of $27,067 million dipped 0.3% from the figure at 2022 end.
Long-term debt, net of the current portion, inched up marginally from the figure as of Dec 31, 2022, to $14,935 million. Short-term debt amounted to $148 million.
THC had no outstanding borrowings under its $1.5 billion line of credit at the end of March-quarter.
Total shareholders’ equity of $1,233 million rose 8% from the 2022-end level.
In the reported quarter, Tenet Healthcare generated operating cash flows of $449 million, which nearly doubled year over year. Free cash flows were recorded at $214 million, which increased nearly three-fold year over year.
Share Repurchase Update
THC bought back common shares worth $50 million in the first quarter. It has a leftover buyback capacity of $700 million that is set to expire by 2024-end.
2Q23 Guidance
Net operating revenues are anticipated to lie within $4,800-$5,000 million.
Adjusted EBITDA is estimated to lie between $765 million and $815 million.
Adjusted net income from continuing operations is forecasted within $115-$140 million.
Adjusted EPS is projected within $1.07-$1.30.
2023 Guidance Revised
Concurrent with the first-quarter results, THC updated its 2023 guidance with respect to certain metrics.
Net operating revenues are currently anticipated to lie between $19,800 million and $20,200 million in 2023, up from the previous outlook of $19,700-$20,100 million. The midpoint of the revised guidance indicates an improvement of 4.3% from the 2022 reported figure.
Net operating revenues of the Hospital Operations and Other segment are predicted to lie between $15,365 million and $15,615 million, while the same at the Ambulatory Care unit is expected within $3,600-$3,700 million. The Conifer segment’s net operating revenues are estimated within $1,285-$1,335 million.
Adjusted EBITDA is forecasted within $3,210-$3,410 million, higher than the prior view of $3,160-$3,360 million. The midpoint of the updated guidance suggests a 4.6% fall from the 2022 figure. Adjusted EBITDA margin is now expected in the 16.2-16.9% band, up from the prior range of 16-16.7%.
Adjusted net income from continuing operations is presently estimated to lie between $530 million and $655 million this year, higher than the earlier view of $505-$630 million. The midpoint of the revised outlook indicates a decline of 20.4% from the 2022 reported figure.
Adjusted EPS is anticipated within $4.92-$6.09, up from the prior outlook of $4.68-$5.85. The midpoint of the revised guidance hints at a 19% plunge from the 2022 figure.
Net cash provided by operating activities is currently forecasted to lie between $1,725 million and $2,025 million, higher than the earlier guidance of $1,700-$2,000 million.
Free cash flow is now expected within $1,100 million-$1,350 million in 2023, up from the previous outlook of $1,075-$1,325 million. Capital expenditures continue to be projected between $625 million and $675 million.
Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Universal Health Services, Inc. (UHS - Free Report) , Humana Inc. (HUM - Free Report) and Boston Scientific Corporation (BSX - Free Report) beat the respective Zacks Consensus Estimate.
Universal Health’s first-quarter 2023 adjusted EPS of $2.34 surpassed the Zacks Consensus Estimate by 8.8% and our estimate of $2.14. Additionally, the bottom line grew 8.8% year over year. Net revenues of UHS advanced 5.3% year over year to $3,468 million in the quarter under review. The top line beat the consensus mark by 1.3% and our estimate of $3,415.5 million. Adjusted EBITDA, net of net income attributable to noncontrolling interests (NCI), amounted to $421.1 million. In the Acute Care Hospital Services segment, adjusted admissions (adjusted for outpatient activity) grew 10.5% year over year on a same-facility basis, while adjusted patient days increased 3.7% year over year.
Humana reported first-quarter 2023 adjusted EPS of $9.38, beating the Zacks Consensus Estimate by 1.4% while missing our estimate of $9.78. The bottom line climbed 16.7% year over year. HUM’s revenues amounted to $26,742 million, surpassing the Zacks Consensus Estimate by 1.6% and our estimate of $26,397 million. The metric rose 11.6% year over year in the quarter under review. Total premiums grew 12.5% year over year to $25,550 million. Revenues from services came in at $999 million, which dropped 21% year over year in the first quarter.
Boston Scientific’s first-quarter 2023 adjusted EPS of 47 cents exceeded the Zacks Consensus Estimate by 9.3%. The bottom line grew 20.5% from the year-ago figure. BSX’s quarterly revenues of $3.39 billion improved 12% year over year on a reported basis and 14.9% on an operational basis (at a constant exchange rate). The top line exceeded the Zacks Consensus Estimate by 7.9%. The gross margin in the first quarter expanded 87 basis points year over year to 69.3%. The cost of products sold increased 8.9% to $1.04 billion.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Tenet Healthcare's (THC) Q1 Earnings Beat, Shares Up 3.9%
Shares of Tenet Healthcare Corporation (THC - Free Report) gained 3.9% since it reported better-than-expected first-quarter 2023 earnings on Apr 25. The strong results stemmed from a well-performing Ambulatory Care segment, expanding patient volumes within the Hospital Operations segment and a moderated pace of contract labor costs. A hiked adjusted earnings per share (EPS) guidance for 2023 might have also instilled investors’ confidence in the stock.
Tenet Healthcare reported first-quarter 2023 adjusted earnings of $1.42 per share, which outpaced the Zacks Consensus Estimate by 22.4% and exceeded management’s expectations. However, the bottom line plunged 25.3% year over year.
Net operating revenues of $5,021 million rose 5.8% year over year in the quarter under review and outperformed the management’s estimate. The top line beat the consensus mark by 4%.
Q1 Performance
Adjusted net income from continuing operations of Tenet Healthcare tumbled 26.7% year over year to $154 million and surpassed management’s expectations. Adjusted EBITDA of $832 million declined 6.3% year over year in the first quarter.
Operating expenses increased 7.8% year over year to $4,471 million mainly due to increased salaries, wages and benefits coupled with higher supplies and other operating expenses. Also, the metric came higher than our estimate of $4,323.9 million.
Tenet Healthcare Corporation Price, Consensus and EPS Surprise
Tenet Healthcare Corporation price-consensus-eps-surprise-chart | Tenet Healthcare Corporation Quote
Segmental Details
Hospital Operations and Other – The segment reported net operating revenues of $3,899 million in the quarter under review, up 2.7% year over year. The reported figure outpaced the Zacks Consensus Estimate of $3,802 million and our estimate of $3,778.4 million. The unit benefited on the back of growing adjusted admissions.
On a same-hospital basis, net patient service revenues inched up 1.1% year over year to $3,547 million.
Adjusted EBITDA of $405 million dropped 21.2% year over year in the first quarter but beat the consensus mark of $362 million. The metric suffered a blow due to declining COVID-related volume and acuity.
Ambulatory Care - Net operating revenues advanced 22.6% year over year to $905 million, higher than the Zacks Consensus Estimate of $829 million and our estimate of $838.1 million. Solid same-facility net surgical case growth, buyouts, the inauguration of new facilities, service line growth and higher pricing yield contributed to the segment’s performance.
Adjusted EBITDA climbed 20.6% year over year to $340 million in the first quarter and beat the consensus mark of $285 million. The metric received an impetus from prudent cost-curbing initiatives.
Conifer – The segment’s net operating revenues of $324 million remained flat year over year in the quarter under review. However, the reported figure surpassed the Zacks Consensus Estimate as well as our estimate of $321 million.
Adjusted EBITDA slid 5.4% year over year to $87 million but beat the consensus mark of $76 million. Earlier disclosed contract changes with Tenet Healthcare’s hospitals hurt the metric.
Financial Position (as of Mar 31, 2023)
Tenet Healthcare exited the first quarter with cash and cash equivalents of $766 million, which decreased 10.7% from the 2022-end figure. Total assets of $27,067 million dipped 0.3% from the figure at 2022 end.
Long-term debt, net of the current portion, inched up marginally from the figure as of Dec 31, 2022, to $14,935 million. Short-term debt amounted to $148 million.
THC had no outstanding borrowings under its $1.5 billion line of credit at the end of March-quarter.
Total shareholders’ equity of $1,233 million rose 8% from the 2022-end level.
In the reported quarter, Tenet Healthcare generated operating cash flows of $449 million, which nearly doubled year over year. Free cash flows were recorded at $214 million, which increased nearly three-fold year over year.
Share Repurchase Update
THC bought back common shares worth $50 million in the first quarter. It has a leftover buyback capacity of $700 million that is set to expire by 2024-end.
2Q23 Guidance
Net operating revenues are anticipated to lie within $4,800-$5,000 million.
Adjusted EBITDA is estimated to lie between $765 million and $815 million.
Adjusted net income from continuing operations is forecasted within $115-$140 million.
Adjusted EPS is projected within $1.07-$1.30.
2023 Guidance Revised
Concurrent with the first-quarter results, THC updated its 2023 guidance with respect to certain metrics.
Net operating revenues are currently anticipated to lie between $19,800 million and $20,200 million in 2023, up from the previous outlook of $19,700-$20,100 million. The midpoint of the revised guidance indicates an improvement of 4.3% from the 2022 reported figure.
Net operating revenues of the Hospital Operations and Other segment are predicted to lie between $15,365 million and $15,615 million, while the same at the Ambulatory Care unit is expected within $3,600-$3,700 million. The Conifer segment’s net operating revenues are estimated within $1,285-$1,335 million.
Adjusted EBITDA is forecasted within $3,210-$3,410 million, higher than the prior view of $3,160-$3,360 million. The midpoint of the updated guidance suggests a 4.6% fall from the 2022 figure. Adjusted EBITDA margin is now expected in the 16.2-16.9% band, up from the prior range of 16-16.7%.
Adjusted net income from continuing operations is presently estimated to lie between $530 million and $655 million this year, higher than the earlier view of $505-$630 million. The midpoint of the revised outlook indicates a decline of 20.4% from the 2022 reported figure.
Adjusted EPS is anticipated within $4.92-$6.09, up from the prior outlook of $4.68-$5.85. The midpoint of the revised guidance hints at a 19% plunge from the 2022 figure.
Net cash provided by operating activities is currently forecasted to lie between $1,725 million and $2,025 million, higher than the earlier guidance of $1,700-$2,000 million.
Free cash flow is now expected within $1,100 million-$1,350 million in 2023, up from the previous outlook of $1,075-$1,325 million. Capital expenditures continue to be projected between $625 million and $675 million.
Zacks Rank
Tenet Healthcare currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Universal Health Services, Inc. (UHS - Free Report) , Humana Inc. (HUM - Free Report) and Boston Scientific Corporation (BSX - Free Report) beat the respective Zacks Consensus Estimate.
Universal Health’s first-quarter 2023 adjusted EPS of $2.34 surpassed the Zacks Consensus Estimate by 8.8% and our estimate of $2.14. Additionally, the bottom line grew 8.8% year over year. Net revenues of UHS advanced 5.3% year over year to $3,468 million in the quarter under review. The top line beat the consensus mark by 1.3% and our estimate of $3,415.5 million. Adjusted EBITDA, net of net income attributable to noncontrolling interests (NCI), amounted to $421.1 million. In the Acute Care Hospital Services segment, adjusted admissions (adjusted for outpatient activity) grew 10.5% year over year on a same-facility basis, while adjusted patient days increased 3.7% year over year.
Humana reported first-quarter 2023 adjusted EPS of $9.38, beating the Zacks Consensus Estimate by 1.4% while missing our estimate of $9.78. The bottom line climbed 16.7% year over year. HUM’s revenues amounted to $26,742 million, surpassing the Zacks Consensus Estimate by 1.6% and our estimate of $26,397 million. The metric rose 11.6% year over year in the quarter under review. Total premiums grew 12.5% year over year to $25,550 million. Revenues from services came in at $999 million, which dropped 21% year over year in the first quarter.
Boston Scientific’s first-quarter 2023 adjusted EPS of 47 cents exceeded the Zacks Consensus Estimate by 9.3%. The bottom line grew 20.5% from the year-ago figure. BSX’s quarterly revenues of $3.39 billion improved 12% year over year on a reported basis and 14.9% on an operational basis (at a constant exchange rate). The top line exceeded the Zacks Consensus Estimate by 7.9%. The gross margin in the first quarter expanded 87 basis points year over year to 69.3%. The cost of products sold increased 8.9% to $1.04 billion.